Browse ACSM2A

Summary
SymbolACSM2A
Nameacyl-CoA synthetase medium-chain family member 2A
Aliases A-923A4.1; MGC150530; Homolog of rat kidney-specific (KS); butyrate--CoA ligase 2A; butyryl-coenzyme A synth ......
Chromosomal Location16p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion matrix
Domain PF00501 AMP-binding enzyme
PF13193 AMP-binding enzyme C-terminal domain
Function

Has medium-chain fatty acid:CoA ligase activity with broad substrate specificity (in vitro). Acts on acids from C(4) to C(11) and on the corresponding 3-hydroxy- and 2,3- or 3,4-unsaturated acids (in vitro) (By similarity).

> Gene Ontology
 
Biological Process GO:0006631 fatty acid metabolic process
GO:0006637 acyl-CoA metabolic process
GO:0006732 coenzyme metabolic process
GO:0006790 sulfur compound metabolic process
GO:0033500 carbohydrate homeostasis
GO:0035337 fatty-acyl-CoA metabolic process
GO:0035383 thioester metabolic process
GO:0036112 medium-chain fatty-acyl-CoA metabolic process
GO:0042593 glucose homeostasis
GO:0051186 cofactor metabolic process
GO:0055088 lipid homeostasis
GO:0055090 acylglycerol homeostasis
GO:0070328 triglyceride homeostasis
Molecular Function GO:0016874 ligase activity
GO:0016877 ligase activity, forming carbon-sulfur bonds
GO:0016878 acid-thiol ligase activity
GO:0047760 butyrate-CoA ligase activity
Cellular Component GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG hsa00650 Butanoate metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-156587: Amino Acid conjugation
R-HSA-211859: Biological oxidations
R-HSA-159424: Conjugation of carboxylic acids
R-HSA-177128: Conjugation of salicylate with glycine
R-HSA-1430728: Metabolism
R-HSA-156580: Phase II conjugation
Summary
SymbolACSM2A
Nameacyl-CoA synthetase medium-chain family member 2A
Aliases A-923A4.1; MGC150530; Homolog of rat kidney-specific (KS); butyrate--CoA ligase 2A; butyryl-coenzyme A synth ......
Chromosomal Location16p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ACSM2A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolACSM2A
Nameacyl-CoA synthetase medium-chain family member 2A
Aliases A-923A4.1; MGC150530; Homolog of rat kidney-specific (KS); butyrate--CoA ligase 2A; butyryl-coenzyme A synth ......
Chromosomal Location16p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ACSM2A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolACSM2A
Nameacyl-CoA synthetase medium-chain family member 2A
Aliases A-923A4.1; MGC150530; Homolog of rat kidney-specific (KS); butyrate--CoA ligase 2A; butyryl-coenzyme A synth ......
Chromosomal Location16p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ACSM2A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5510.262
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.9640.195
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7870.314
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2090.888
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.5110.357
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3890.693
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2030.52
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6560.728
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2960.903
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7250.825
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.8950.0139
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ACSM2A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.79.6-5.90.679
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.710.2-6.50.425
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.817.66.20.709
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.127.3-4.21
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.27.45.80.69
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.27.710.50.63
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolACSM2A
Nameacyl-CoA synthetase medium-chain family member 2A
Aliases A-923A4.1; MGC150530; Homolog of rat kidney-specific (KS); butyrate--CoA ligase 2A; butyryl-coenzyme A synth ......
Chromosomal Location16p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACSM2A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolACSM2A
Nameacyl-CoA synthetase medium-chain family member 2A
Aliases A-923A4.1; MGC150530; Homolog of rat kidney-specific (KS); butyrate--CoA ligase 2A; butyryl-coenzyme A synth ......
Chromosomal Location16p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACSM2A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACSM2A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolACSM2A
Nameacyl-CoA synthetase medium-chain family member 2A
Aliases A-923A4.1; MGC150530; Homolog of rat kidney-specific (KS); butyrate--CoA ligase 2A; butyryl-coenzyme A synth ......
Chromosomal Location16p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACSM2A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolACSM2A
Nameacyl-CoA synthetase medium-chain family member 2A
Aliases A-923A4.1; MGC150530; Homolog of rat kidney-specific (KS); butyrate--CoA ligase 2A; butyryl-coenzyme A synth ......
Chromosomal Location16p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ACSM2A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolACSM2A
Nameacyl-CoA synthetase medium-chain family member 2A
Aliases A-923A4.1; MGC150530; Homolog of rat kidney-specific (KS); butyrate--CoA ligase 2A; butyryl-coenzyme A synth ......
Chromosomal Location16p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ACSM2A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolACSM2A
Nameacyl-CoA synthetase medium-chain family member 2A
Aliases A-923A4.1; MGC150530; Homolog of rat kidney-specific (KS); butyrate--CoA ligase 2A; butyryl-coenzyme A synth ......
Chromosomal Location16p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ACSM2A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.